Navigation Links
Comparison of antipsychotic treatments in adolescents with schizophrenia
Date:2/28/2008

Philadelphia, PA, February 28, 2008 There is a wealth of scientific literature available on the treatment of adults diagnosed with schizophrenia. However, there is a paucity of data to guide the treatment of children and adolescents with schizophrenia. Although the U.S. Food and Drug Administration (FDA) has recently approved the use of aripiprazole and risperidone for adolescents with schizophrenia, few controlled data are available to help guide clinicians regarding the management of children and adolescents with schizophrenia who fail to respond to these standard 'first-line' antipsychotic treatments, according to Dr. Sanjiv Kumra. Dr. Kumra is one of the authors of a new study to be published in the March 1st issue of Biological Psychiatry, which was undertaken to help fill this gap in knowledge.

The authors recruited 39 children, 10-18 years of age, who had already failed to respond to at least two antipsychotic treatments, to participate in a 12-week, double-blind, randomized study the most rigorous of clinical trial designs. After initial assessments, the patients received treatment with either clozapine or high-dose olanzapine (doses that exceed the package insert recommendations) and were monitored for improvement in their symptoms. The researchers discovered that clozapine was approximately twice as likely to produce a treatment response as olanzapine. Both positive symptoms (psychosis) and negative symptoms (blunted emotional response, reduced motivation) responded better to clozapine. John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments on the findings: Olanzapine is among the most effective antipsychotic medications, so the distinctive effectiveness of clozapine in this study could be very important.

Dr. Kumra discusses this patient population: The majority of these youth had histories of multiple hospitalizations, extreme violence, suicidality and trauma prior to study enrollment. Without appropriate intervention it is likely that many would have ended up in long-term care institutions, psychiatric prison settings, and/or experienced early death from drug use, violence, or suicide. So, this preliminary data is hopeful, indicating that proper and effective treatment may be available for these adolescents, although there are also concerns.

Both medications produced significant weight gain and associated metabolic abnormalities. Dr. Krystal also adds that clozapine has important side effects that have discouraged its prescription to children. Dr. Kumra agrees, stating that although clozapine is often considered as a treatment of last resort because of its associated risk of agranulocytosis [a severe reduction in the number of white blood cells in the body], the striking symptom reduction observed in this clinical trial make apparent that clozapine has truly revolutionized the care of youth with treatment-refractory schizophrenia.

Dr. Krystal concludes: The long-term risks of medications, such as clozapine and olanzapine, will need to be weighed against their potential benefits. Thus, additional research will be needed to follow-up on this exciting but very preliminary finding.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
3. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
5. Diuretics excel in drug comparison trial involving hypertension/metabolic syndrome
6. Comparison of venlafaxine and SSRIs in the treatment of depression
7. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
8. Antidepressant as Good as Antipsychotics for Dementia
9. Some antipsychotic drugs may be missing their mark
10. Weight gain induced by antipsychotic drugs can be avoided
11. Drug-free treatments offer hope for older people in pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly popular ... bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top finisher ... in less than a year was able to turn professional, participating in the 2013 ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
(Date:1/21/2017)... ... January 21, 2017 , ... "ProDOF is the perfect set of tools for video ... subject in a scene," said Christina Austin - CEO of Pixel Film Studios. , ... Easily create the illusion of a DSLR racking focus from one area into the next. ...
(Date:1/21/2017)... ... 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is excited ... 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam rooms, ... services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema Pourtaheri ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 Longer life expectancy and rising healthcare expenditure ... for medical device technologies. BCC Research reveals in its new ... region, should see strong growth due to rising government healthcare ... Continue Reading ... ...
(Date:1/23/2017)... -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: ... agreement with the Children,s Hospital of Philadelphia ... US key opinion leader in the mitochondrial medicine field. ... Dr. ... research program, NVP015, in certain experimental disease models. The research ...
(Date:1/21/2017)... -- ResMed (NYSE: RMD ), BMC ( Beijing, ... ) today announced they have agreed on a global settlement ... permitted to sell their existing products in exchange for royalty payments ... 3B to close the Florida litigation between ... liability or wrongdoing by any party. The five-year ...
Breaking Medicine Technology: